Current Management of Scalp Psoriasis.

Current Management of Scalp Psoriasis. Skin Therapy Lett. 2015 Jun;20(3):5-7 Authors: Guenther L Abstract The scalp is involved in up to 80% of individuals with psoriasis. Eighty percent of those with scalp psoriasis experience a negative impact on quality of life. Topical treatment with corticosteroids with or without vitamin D3 analogues is the mainstay of treatment. Topical therapy most suitable for the scalp is formulated as a solution, lotion, gel, foam, spray, oil, or shampoo. Twice weekly maintenance in frequent relapsers may decrease the time to first relapse. Intralesional steroids, phototherapy and the excimer laser are occasionally used for resistant cases. In patients with moderate-to-severe psoriasis, apremilast, adalimumab and etanercept have been shown to significantly improve scalp psoriasis. They should be considered in patients who have failed topical therapy. PMID: 26382557 [PubMed - in process]
Source: Skin Therapy Letter - Category: Dermatology Authors: Tags: Skin Therapy Lett Source Type: research

Related Links:

Authors: Bhatia ND, Vlahovic TC, Green LG, Martin G, Lin T Abstract Background: Psoriasis is a chronic, immune-mediated disease that varies widely in its clinical expression. Topical corticosteroids (TCS) are the mainstay of treatment. Long-term safety remains a concern, limiting use, and posttreatment flare is common. Recently data were reported on the use of halobetasol propionate (HP) 0.01% lotion in moderate or severe localized plaque psoriasis, once-daily for 8 weeks. In addition, a 2-week label-restricted study reported comparable efficacy to HP 0.05% cream. Data evaluating efficacy in specific locations has ...
Source: Journal of Drugs in Dermatology - Category: Dermatology Tags: J Drugs Dermatol Source Type: research
Authors: Piaserico S, Linder D, Messina F, Alaibac M Abstract In the present case report, a 32-year-old man with a 20-year long history of psoriasis, who presented with severe lower back pain and had no records of previous trauma, is reported. The patient reported the regular use of clobetasol cream, for 8 years, at an average dosage of 100 grams (g) per week. At the time of visit, the patient presented with severe psoriasis, which was associated with a cushingoid appearance. An X-ray of the spine was performed and the results revealed diffuse vertebral collapse that was caused by osteoporosis. The patient was diag...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
DUOBRII™ (Halobetasol Propionate and Tazarotene) Lotion for Topical Use: A Newly Approved Combination Corticosteroid and Retinoid Topical Treatment of Plaque Psoriasis in Adults. Skinmed. 2019;17(3):181-183 Authors: Gupta AK, Love RP, Abramovits W, Vincent KD PMID: 31496472 [PubMed - in process]
Source: Skinmed - Category: Dermatology Authors: Tags: Skinmed Source Type: research
Background: Topical corticosteroids are available in many vehicles. However, patients' preference for vehicles are variable and could be tailored to maximize patient adherence. Spray vehicles may offer, convenience, and strong efficacy. Methods: A literature review was conducted using keywords: clobetasol, desoximetasone, betamethasone, triamcinolone, corticosteroid, topical, spray, vehicles, treatment, and clinical trial. Results: For moderate-to-severe plaque psoriasis, 87% of subjects achieved an Overall Disease Severity (ODS) Score ≤2 at week two and 78% achieved an ODS ≤1 after four weeks with clobetasol propion...
Source: Dermatology Online Journal - Category: Dermatology Source Type: research
Topical corticosteroid is a widely used for treatment of psoriasis. However, its long-term use may bring about resistance to the treatment. We have previously shown that multiple drug resistance 1 (MDR1)-expressing T cells infiltrate in the skin lesions of psoriasis, especially at the skin treated with a corticosteroid. Corticosteroids are a substrate of MDR1, and possible association of MDR1+ T cells and corticosteroid resistance has been documented in some diseases. Since MDR1+ T cells in psoriatic skin include a large number of IL-17A and IL-22-producing cells, they can be associated with corticosteroid resistance.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Clinical Research and Epidemiology Source Type: research
Conclusion: This new anti-inflammatory emollient appears to be a helpful addition to the treatment armamentarium for eczema and psoriasis that may reduce reliance on topical corticosteroids and immunomodulators. PMID: 31447573 [PubMed]
Source: Clinical, Cosmetic and Investigational Dermatology - Category: Dermatology Tags: Clin Cosmet Investig Dermatol Source Type: research
AbstractElderly patients are a group with a high frequency of psoriasis. Their disease burden has negative impacts on their quality of life. While there is a clear need to treat these patients, there are challenges in doing so. This work seeks to define the challenges that exist in treating elderly Medicare patients, as well as to provide treatment suggestions for providers to follow if they encounter one or more of these challenges. Providers face the following challenges when creating treatment plants for elderly patients with psoriasis: difficulty in obtaining drug coverage through Medicare, increased medical comorbidit...
Source: American Journal of Clinical Dermatology - Category: Dermatology Source Type: research
This study aimed to elucidate and compare such effects in a human Th17 skin inflammation model.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
Background: Psoriasis is a chronic, immune-mediated disease that varies widely in its clinical expression. Topical corticosteroids (TCS) are the mainstay of treatment. Long-term safety remains a concern, limiting use, and posttreatment flare common. Tazarotene has also been shown to be effective in psoriasis, with efficacy maintained several weeks posttreatment. Fixed combination therapy with TCS may improve psoriasis signs and may maintain a therapeutic effect while minimizing posttreatment flare or rebound
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
Background: Topical corticosteroids may lose efficacy over time. Poor treatment outcomes may be due to poor adherence. We evaluated how frequently patients with psoriasis resistant to topical treatment respond to topical corticosteroids
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
More News: Corticosteroid Therapy | Dermatology | Enbrel | Humira | Psoriasis | Skin | Vitamins